Anzeige
Mehr »
Freitag, 26.09.2025 - Börsentäglich über 12.000 News
Hot Stock: KI-Boom treibt Kupfer in neue Dimensionen - jetzt profitieren!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2DG49 | ISIN: US4834971032 | Ticker-Symbol: 4XC1
Tradegate
26.09.25 | 10:26
10,200 Euro
-1,92 % -0,200
1-Jahres-Chart
KALVISTA PHARMACEUTICALS INC Chart 1 Jahr
5-Tage-Chart
KALVISTA PHARMACEUTICALS INC 5-Tage-Chart
RealtimeGeldBriefZeit
10,30010,60016:55
10,30010,50016:54

Aktuelle News zur KALVISTA PHARMACEUTICALS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
13:06KalVista Pharmaceuticals, Inc.: KalVista Pharmaceuticals to Present New EKTERLY (sebetralstat) Data at the 20th German Allergy Congress182KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced the acceptance of six abstracts for ePoster presentation at the 20th German Allergy Congress taking place in Düsseldorf, Germany from...
► Artikel lesen
DoKalVista prices upsized offering of $125M of 3.250% notes due 20311
DoKalVista prices $125 million convertible senior notes offering1
DoKalVista Pharmaceuticals, Inc.: KalVista Prices Upsized Offering of $125.0 Million of 3.250% Convertible Senior Notes Due 2031323KalVista Pharmaceuticals, Inc. ("KalVista") (NASDAQ: KALV), announced today the pricing of its offering of $125.0million aggregate principal amount of 3.250% Convertible Senior Notes due 2031 (the...
► Artikel lesen
MiKalVista to offer $110M in convertible notes; shares down 10%3
MiKalvista Pharmaceuticals stock falls after convertible notes offering1
MiKalVista plans to offer $110 million in convertible notes3
KALVISTA PHARMACEUTICALS Aktie jetzt für 0€ handeln
MiKalVista Pharmaceuticals, Inc.: KalVista Pharmaceuticals Announces Proposed Offering of $110.0 Million of Convertible Senior Notes263KalVista Pharmaceuticals, Inc. ("KalVista") (NASDAQ: KALV) announced today that it intends to offer, subject to market conditions and other factors, $110.0million aggregate principal amount of Convertible...
► Artikel lesen
19.09.KalVista, Ionis/Sobi among latest to win EU nod for rare disease drugs2
19.09.KalVista's oral HAE treatment Ekterly receives EU and Swiss approval2
19.09.KalVista Pharmaceuticals, Inc.: KalVista Pharmaceuticals Announces European Commission and Swissmedic Approval of EKTERLY (sebetralstat), First and Only Oral On-Demand Treatment for Hereditary Angioedema304First European launch of EKTERLY expected in Germany Q4 2025 EKTERLY now approved in the US, EU, UK and Switzerland with additional regulatory applications under review in key global markets...
► Artikel lesen
12.09.Kalvista stock price target raised to $28 from $27 at JMP on strong Ekterly demand9
11.09.KalVista stock price target lowered to $36 by BofA on Ekterly launch data5
11.09.BofA senkt Kursziel für KalVista nach Daten zur Ekterly-Einführung auf 36 US-Dollar3
11.09.KalVista Pharma überrascht mit starkem Umsatz im Q1 2026 - Aktie legt trotz höherem Verlust zu3
11.09.KalVista Pharmaceuticals, Inc. - 10-Q, Quarterly Report1
11.09.KalVista Pharmaceuticals, Inc. - 8-K, Current Report1
11.09.Kalvista Pharma: EPS verfehlt Schätzungen um 0,16 $ - Umsatz besser als erwartet5
11.09.KalVista Pharmaceuticals, Inc.: KalVista Pharmaceuticals Provides Operational Update and Reports Fiscal Quarter Financial Results269-EKTERLY® now approved in the US and UK; first and only oral on-demand therapy for acute attacks of hereditary angioedema- -Initiated US EKTERLY launch in July; received 460 patient start forms...
► Artikel lesen
11.09.KalVista Pharmaceuticals GAAP EPS of -$1.12 misses by $0.17, revenue of $1.43M misses by $0.66M3
Weiter >>
124 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1